The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
|Videos|May 23, 2017
Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).
Advertisement
Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).
Advertisement
Related to this article
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5